IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors

Company Overview - IDEAYA Biosciences, Inc. is a precision medicine oncology company focused on discovering and developing targeted therapeutics using molecular diagnostics [12] - Jiangsu Hengrui Pharmaceuticals Co., Ltd. is an innovative global pharmaceutical company with a strong emphasis on unmet clinical needs and has invested over 5.4 billion in R&D since 2011 [4] Licensing Agreement - IDEAYA has entered into an exclusive license agreement with Hengrui Pharma for SHR-4849, a DLL3-targeting Topo-I-payload ADC program, for development and commercialization outside of Greater China [1][8] - Hengrui Pharma is eligible to receive total payments of 1.045 billion, including a $75 million upfront fee and up to$200 million in development and regulatory milestone payments [8] Clinical Development - SHR-4849 is currently in a Phase 1 clinical trial for advanced solid tumors in China, showing promising antitumor activity with an overall response rate of approximately 73% in evaluable small cell lung cancer subjects [7][11] - The drug targets DLL3, which is highly expressed in small cell lung cancer (85%) and neuroendocrine tumors (20-40%), making it a significant therapeutic target [6][11] Strategic Objectives - IDEAYA aims to file a US IND for SHR-4849 in the first half of 2025, aligning with its strategic objective to develop rational clinical combinations with its PARG inhibitor IDE161 [2][6] - The collaboration with Hengrui Pharma supports IDEAYA's goal of delivering innovative medicines globally, addressing significant unmet medical needs in DLL3-expressing solid tumors [2][6]